IR Notice
Dear Shareholders,
Samsung Biologics has always had always had a willingness to innovate, to take risks, and to confront challenges, which is why we are excited to announce our Plant 4 expansion plan.
To say that this is a huge milestone achieved is an understatement. We’ve come a long way in a short period of time: Plant 1 had its ground breaking in 2011, Plant 2 in2013, and Plant 3 in 2015. Currently, utilization of Plant 1 and 2 remains high, and we continue to add contracts to Plant 3 from clients whose primary requests include a secure stable manufacturing supply. At Samsung Biologics, innovation isn’t something we do in bursts or sporadically. It is a constant approach, and the biopharmaceutical industry has recognized this trait through our outstanding quality, cost competitiveness, and customer satisfaction over the years. Taking into consideration the market’s supply and demand and the trend of global pharmaceutical companies expanding their usage of CMPs, we see the Plant 4 expansion as our long-term strategy for resilience and growth not only for ourselves but for our clients as well.
| Capacity | 256,000L |
|---|---|
| CAPEX Amount | 1.74 trillion Korean Won |
| Targeted Construction Period |
|
| Location & Size |
|
Plant 4 will have the world’s largest manufacturing capacity at a single site with top-notch quality and production efficiency – using Samsung Biologics’ cutting-edge plant design technology. Also in order to respond to our clients’ diverse requests with even more flexibility, we will leverage a variety of bioreactor sizes (2,000L, 10,000L, and 15,000L).
Upon Plant 4’s completion, Samsung Biologics will have a total site capacity of 620,000 liters, setting us on track to be one of the world’s largest CDMO companies. We recognize that we’re entering into a new era for biomanufacturing that requires us to go beyond the standard: we need to innovate through technology and product construction to create this super gap between us and our competitors.
In addition to our Plant 4 expansion, we are also reviewing the creation of a second bio complex in Songdo, Incheon. We’re investing in these advancements because our future and the future of healthcare depends on it. We promise to continue to deliver long-term growth and value for our shareholders, whose success and Samsung Biologics’ success are inextricably linked.
Sincerely,
Tae Han Kim
President & CEO, Samsung Biologics
August 11, 2020
